Is dabrafenib a new generation of targeted drug? Belong to several generations

Dabrafenib (Dabrafenib) belongs to a new generation of targeted drugs. It is a drug designed for specific molecular targets and is mainly used to treat melanoma and non-small cell lung cancer related to BRAF V600 gene mutations. This gene mutation is common in cancer cells, and dabrafenib can selectively inhibit the mutated BRAF kinase, thereby blocking the proliferation and viability of cancer cells. Dabrafenib is a first- or second-generation targeted drug that has a high selectivity for BRAF V600 gene mutations.

Targeted drugs are usually divided into several generations according to their development time and mechanism of action: first generation, second generation and third generation. The first generation of targeted drugs are mostly older drugs that have a wider range of effects, but may also be accompanied by more side effects. Compared with the first generation, the second generation targeted drugs act on specific targets more precisely and have better efficacy and safety. The third generation of targeted drugs has further optimized efficacy and safety and may have a wider range of indications.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).